What’s going on at Grail?

T

here are plenty of reasons to envy Grail, the Google-backed company seeking to revolutionize how cancer is diagnosed. The company has raised more than $1 billion, pulled off a series of high-profile hires, and made a splash in the New England Journal of Medicine.

But organizational stability may not be one of them.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

What is STAT Plus?

About the Author

Damian Garde

National Biotech Reporter

Damian covers biotech and writes The Readout newsletter.

damian.garde@statnews.com

@damiangarde

Tags

biotechnology

genetics

STAT Plus